Monday, June 15, 2026

Samyang’s 3S Sugar Reduction Solution: A Game-Changer for Food Developers—Save Time and Costs in 2026

Samyang Corporation showcases AI-driven sugar reduction solutions at NPEW 2023, aiming to enhance its global market presence.

Analysis: China to Pressure South Korea Over US Military Presence and Trade in APEC

Foreign Minister Cho Hyun visits China to discuss bilateral relations, APEC, and North Korea, amid U.S.-China tensions.

Will Novo Nordisk’s 50% Price Cut on Wegovy Spark a Price War in Korea’s Obesity Drug Market?

Novo Nordisk's price cuts for GLP-1 obesity treatments in the U.S. may influence South Korean market dynamics, though immediate effects seem limited.

Tag: obesity

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Can GLP-1 Medications Reduce Breast Cancer Risk? New Research Reveals Surprising Findings

GLP-1 drugs show promise in cancer prevention and progression inhibition, expanding beyond obesity treatment to chronic disease management.

AstraZeneca’s Elecoglipron: Can This New Weight Loss Pill Compete with GLP-1 Giants?

AstraZeneca's new weight-loss pill, elecoglipron, shows promising results in trials, competing with existing obesity treatments.

Inventage Lab Secures Patent for Semaglutide Formulation Aimed at Improving Oral Bioavailability

Inventage Lab secures a patent for a liposome formulation enhancing semaglutide's bioavailability, aiming to lead in obesity treatment.

Novo Nordisk’s Oral Wegovy Just Put Up a Number That Could Change the Obesity Drug Race

Novo Nordisk's oral obesity treatment, Wegovy, saw $400M in Q1 2026 sales, exceeding estimates and indicating strong market demand.

D&D Pharmatech signs $1.24 million obesity drug research deal with Pfizer

D&D Pharmatech partners with Pfizer for a $1.24M obesity treatment project, marking a significant revenue milestone for the company.

Unlocking Weight Loss: How GB102 Probiotics Enhance GLP-1 Obesity Drugs

GI Longevity's GB102 probiotic enhances weight loss with GLP-1 medications, reducing rebound gain and improving blood sugar control.

JW Pharmaceuticals Secures Exclusive Rights for Innovative GLP-1 Drug Vopaglutide in South Korea

JW Pharmaceutical secures exclusive rights for Vopaglutide, a promising treatment for diabetes and obesity, with significant milestone payments.

Sam Chun Dang Pharm Signs 100 Million USD Licensing Deal for Oral Generics of Rybelsus and Wegovy

Sam Chun Dang Pharm secures a U.S. licensing deal for generic diabetes and obesity medications, valued at $100 million.

Inventage Lab Secures 985 Billion KRW: What This Means for Long-Lasting Injection Solutions

Inventage Lab secures 985 billion KRW to enhance its drug delivery platform, focusing on long-acting injectables for obesity and more.

GLP-1 Weight Loss Injections: Are They Causing Gallstone Surge in Asia?

GLP-1 obesity treatments are linked to increased gallstone risk, especially during rapid weight loss, with cases doubling in South Korea.

Novo Nordisk Slashes GLP-1 Drug Prices by Up to 50%: What This Means for Obesity Treatments in 2027

Novo Nordisk will cut prices of GLP-1 treatments in the U.S. by up to 50% from January 2027, amid rising competition and market pressures.

Hanmi Posts Record $1.16B Sales and $193M Operating Profit: What’s Driving the 2025 Surge

Hanmi Pharmaceutical reports record sales of $1.16 billion in January 2025, with significant growth in profits and new product launches.

How a 2-Cent Sugar Tax Could Save $4.5 Billion in Healthcare Costs: California’s Bold Move

A sugar-sweetened beverage tax in California could cut obesity cases and save $4.5 billion in healthcare costs over ten years.

Chinese Biotech’s Rise: What’s the Standard of Global Tech Trade?

Analysts at the JPMHC noted a shift in biotech, with firms resisting sales and China emerging as a tech transfer leader.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.